Thymalin

Typical use cases

Dosing guidelines

Titration

Typically run as fixed short courses (about 5-10 consecutive days) rather than gradual titration, with courses repeated periodically (e.g., 1-2x/year) in reported longevity protocols. Educational only and not a recommendation to start, stop, or change any dose.

Reconstitution

Lyophilized powder; the official medical product is reconstituted with sterile isotonic saline (0.9% NaCl) for intramuscular use, while community protocols often use bacteriostatic or sterile water. Add diluent slowly down the vial wall and swirl gently rather than shaking. Reconstituted solution is commonly stored refrigerated and used within roughly 28 days.

Injection sites

Primarily intramuscular (deltoid or gluteal) in official use; subcutaneous administration (abdomen, thigh, upper arm) is also used in community protocols

Storage & handling

Store lyophilized vials refrigerated at 2-8°C and protected from light; keep any reconstituted solution refrigerated (2-8°C) and avoid freezing.

Side effects

• Injection site reaction (redness, swelling, pain) Mild · Common
• Flu-like symptoms (fever, fatigue, muscle aches) Mild · Uncommon
• Gastrointestinal upset (nausea, diarrhea) Mild · Uncommon
• Rash / skin irritation Mild · Uncommon
• Allergic / hypersensitivity reaction Severe · Rare
• Changes in blood cell counts Moderate · Rare

Research summary

Thymalin is a low-molecular-weight polypeptide complex obtained by mild acid extraction from the thymus glands of young calves, developed in the USSR in the 1970s and registered for clinical use (as Timalin) in Russia and several former Soviet states. Mechanistically, its short regulatory peptides are reported to promote T-lymphocyte differentiation and maturation, modulate natural killer and dendritic cell activity, and help normalize cytokine balance, acting primarily on the thymus-dependent (T-system) arm of immunity; its active dipeptides Lys-Glu (KE) and Glu-Trp (EW) have been characterized in more recent molecular work. The most cited human evidence is a 6-to-8-year observational program by Khavinson and Morozov in 266 elderly subjects that reported roughly a 1.6-to-2-fold reduction in mortality with Thymalin and up to about a 4.1-fold reduction when combined with the pineal peptide Epithalamin, alongside fewer acute respiratory illnesses and improved cardiovascular, endocrine and immune markers. More recent reviews of thymic peptides and exploratory COVID-era reports have revisited its immunomodulatory potential. However, the evidence base has major limitations: the landmark longevity data come from non-blinded, non-randomized Soviet/Russian programs not replicated in Western randomized controlled trials, sample sizes are modest, methodology is poorly standardized by current norms, and because Thymalin is a biological extract rather than a single defined molecule its composition can vary by manufacturer. It is not FDA-approved, and most anti-aging claims remain unconfirmed by modern controlled human research.

Key references

• https://pubmed.ncbi.nlm.nih.gov/14523363/
• https://pubmed.ncbi.nlm.nih.gov/9637345/
• https://doi.org/10.1007/s10989-024-10666-y
• https://pmc.ncbi.nlm.nih.gov/articles/PMC10488166/
• https://clinmedjournals.org/articles/ijii/international-journal-of-immunology-and-immunotherapy-ijii-7-055.pdf

Related compounds